Checkpoint kinase (CHK) 1/2 inhibitor LY2606368 in a phase I, doseexpansion study in patients (pts) with metastatic squamous cell carcinoma (mSCC) of the anus

Authors
Category Primary study
JournalJournal of Clinical Oncology
Year 2015
This article has no abstract
Epistemonikos ID: 6fbc53b90bc95b12c247516e49bb023522380b0a
First added on: Feb 07, 2025